HUTCHMED Data to be Presented at EHA2024 Congress | Company

Investegate announcements from HUTCHMED Data to be Presented at EHA2024 Congress

Related Keywords

Spain , Cheng Mei , Guangdong , China , Oslo , Norway , Hong Kong , Tianjin , Houston , Texas , United States , Beijing , Shanghai , Huazhong , Hubei , Valencia , Carabobo , Venezuela , Madrid , Tongji , Sichuan , Ying Qian , Jiangxi , Peking , Wuhan , Chinese , Fengkui Zhang , Waleed Ghanima , Zhou Yi , Sovleplenibin Heavilypre , Pau Montesinos , Tazemetostatplus Amdizalisib , Xiaojun Huang , Ben Atwell Alex Shaw , Mingci Cai , Xiaofan Liu , Atholl Tweedie , Renchi Yang , Hall Mallo , University Of Oslo , Institute Of Hematologyandblood Diseases Hospital , University People Hospital , Huazhong University Of Science , Chinese Academy Of Medical Sciences , Nasdaq , Exchange Commission , China Limited , Institute Of Hematology , Union Hospital , Tongji Medical College , Shanghai Jiao Tong University Schoolof Medicine , Linkedin , European Hematology Association , University Of Texas Md Anderson Cancer Center , Stock Exchange Of Hong Kong , Sovleplenib Phase , Hematological Malignancy Programs Data , Florham Park , Hybrid Congress , Immune Thrombocytopenia , Syk Inhibitor Sovleplenib , Adult Patients , Primary Immune Thrombocytopenia , Placebo Controlled Phase , Blood Diseases Hospital , Chinese Academy , Medical Sciences , Warm Antibody Autoimmune Hemolytic Anemia , Hematologyandblood Diseases Hospital , Prior Lines , Subgroup Analysis , Huazhong University , Cancer Center , Final Resultofdose Expansionin Phase , University People , Preliminary Resultsofthe Dose , Escalation Study , Third Generation , Highly Selective , Chinese Patients , Preliminary Efficacy , Syk Inhibitor , Adult Subjects , Securities Litigation Reform Act , Stock Exchange , Hong Kong Limited , Alex Shaw ,